Prazosin as an Antimanic Agent in Severe Mania or Mixed States
Overview
Mania has been considered to be, in part, a hyperadrenergic state. One focus of treatment of mania involves directly targeting this hyperexcitable state by reducing arousal with antiadrenergic agents. This can be achieved by decreasing norepinephrine release by stimulating presynaptic inhibitory receptors. Prazosin, FDA approved for the treatment of high blood pressure works in part by blocking postsynaptic alpha-adrenergic receptors. Prazosin has been found to be clinically useful for the treatment of Post Traumatic Stress Disorder. It is reasonable, therefore, to anticipate that prazosin might be helpful in the treatment of mania.
Full Title of Study: “Prazosin as an Antimanic Agent in Severe Mania or Mixed Episodes: a Double-blind, Placebo-controlled Study”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Double (Participant, Investigator)
- Study Primary Completion Date: November 2009
Interventions
- Drug: Addition of prazosin to usual care (add-on study)
- Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day’s dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
- Drug: Placebo
- Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day’s dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
Arms, Groups and Cohorts
- Active Comparator: prazosin
- Add prazosin to usual medications and monitor manic symptoms and for adverse effects
- Placebo Comparator: Placebo
Clinical Trial Outcome Measures
Primary Measures
- Young Mania Rating Scale (YMRS)
- Time Frame: 10 days
Secondary Measures
- Mania Acute Changes Scale (MACS)
- Time Frame: 10 days
Participating in This Clinical Trial
Inclusion Criteria
- Age 18-60 – Primary diagnosis of bipolar disorder with severe mania or mixed episode – YMRS score of > 20 – Documented medical evaluation without acute or serious medical illness – Negative pregnancy test – Healthy functioning liver Exclusion Criteria:
- Lack of capacity to provide informed consent – Involuntary commitment – Low blood pressure – History of adverse reaction or allergy to prazosin or other quinazolines – Informed consent not given or retracted during study – History of narcolepsy – Unstable or acute medical illness
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 60 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Mclean Hospital
- Provider of Information About this Clinical Study
- Principal Investigator: Elizabeth S. Liebson, PI – Mclean Hospital
- Overall Official(s)
- Elizabeth S Liebson, MD, Principal Investigator, Mclean Hospital
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.